Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,591.36 75.09 0.52%
TOPIX 1,178.97 5.60 0.48%
HANG SENG 22,760.24 64.23 0.28%

Algeta to Participate in Upcoming Investor Conference


Algeta to Participate in Upcoming Investor Conference

OSLO, NORWAY -- (Marketwired) -- 04/17/13 -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and IR teams will participate in the following investor conference:

Kempen & Co. 6(th) Healthcare/Life Sciences Conference

Date: 23 April 2013

Participants:

Thomas Ramdahl (Chief Technology Officer)

Renate Birkeli (IR)

Venue: Amsterdam, The Netherlands

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

Algeta to Participate in Upcoming Investor Conference:

http://hugin.info/134655/R/1693399/556601.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE

[HUG#1693399]

For further information, please contact:

Mike Booth / Renate Birkeli +47 23 00 67 32 Communications & Corporate Affairs ir@algeta.com

Media enquiries:

Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk

Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton knut.ekern@hkstrategies.com

Kari Watson +1 781 235 3060 MacDougall Biomedical Communications kwatson@macbiocom.com

US investor enquiries: Tricia Swanson +1 646 378 2953

The Trout Group tswanson@troutgroup.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement